CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 4, 2017--
bluebird bio, Inc. (Nasdaq:
BLUE), a clinical-stage company committed to developing potentially
transformative gene therapies for severe genetic diseases and T
cell-based immunotherapies for cancer, announced today that Nick
Leschly, chief bluebird, will present at the 35th annual J.P. Morgan
Healthcare Conference on Wednesday, January 11, 2017 at 10:00 a.m. PST.
The conference is being held January 9-12, 2017 at the Westin St.
Francis in San Francisco.
To access the live webcast of bluebird bio’s presentation and subsequent
breakout session, please visit the “Calendar of Events” page within the
Investors and Media section of the bluebird bio website at http://investor.bluebirdbio.com.
Replays of the webcast will be available on the bluebird bio website for
90 days following the conference.
This release contains
“forward-looking statements” within the meaning of the Private
Securities Litigation Reform Act of 1995, including statements regarding
the Company’s product candidates and research programs. Any
forward-looking statements are based on management’s current
expectations of future events and are subject to a number of risks and
uncertainties that could cause actual results to differ materially and
adversely from those set forth in or implied by such forward-looking
statements. These risks and uncertainties include, but are not limited
to, risks that the preliminary results from our clinical trials will not
continue or be repeated in our ongoing clinical trials, the risk of
cessation or delay of any of the ongoing or planned clinical studies
and/or our development of our product candidates, the risk of a delay in
the enrollment of patients in our clinical studies, risks that the
current or planned clinical trials of the LentiGlobin drug product will
be insufficient to support regulatory submissions or marketing approval
in the United States and European Union, the risk that our
collaborations, including the collaboration with Celgene, will not
continue or will not be successful, and the risk that any one or more of
our product candidates will not be successfully developed, approved or
commercialized. For a discussion of other risks and uncertainties, and
other important factors, any of which could cause our actual results to
differ from those contained in the forward-looking statements, see the
section entitled “Risk Factors” in our most recent quarterly report on
Form 10-Q, as well as discussions of potential risks, uncertainties, and
other important factors in our subsequent filings with the Securities
and Exchange Commission. All information in this press release is as of
the date of the release, and bluebird bio undertakes no duty to update
this information unless required by law.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170104005345/en/
Source: bluebird bio, Inc.
bluebird bio, Inc.
Manisha Pai, 617-245-2107
Elizabeth Pingpank, 617-914-8736
Dan Budwick, 973-271-6085